Aurinia Pharmaceuticals AUPH Taxes withheld related to vesting of performance awards

Taxes withheld related to vesting of performance awards at other companies

Amylyx Pharmaceuticals, Inc.AMLX

$3.94M+345%

OUTFRONT MediaOUT

$2.8M+7.7%

NovoCureNVCR

$556K—

Gaming and Leisure PropertiesGLPI

-$6.26M+57.7%

BioCryst PharmaceuticalsBCRX

$3.17M+1,049%

Curbline PropertiesCURB

$3.54M+19.1%

Other financials

Income statement

See full

Revenue$77.7M+24.4%

Gross profit$71.2M+32.1%

Operating income$41.4M+89.6%

Net income$34.4M+47.2%

EPS (diluted)$0.25+56.3%

Balance sheet

See full

Cash & equivalents$41.0M-38.3%

Total debt$85.2M-7.9%

Total equity$567.6M+62.1%

Total assets$724.0M+43.4%

Cash flow

See full

Operating cash flow$32.6M+2,405%

Valuation

See full

Market cap$2.3B+78.5%

Enterprise value$2.34B+78.3%

P/E7.7×-24.6×

P/S7.7×+2.5×

Profitability

See full

Gross margin89.7%+1.5pp

Operating margin41.7%+29.4pp

Net margin100%+83.9pp

Returns & leverage

See full

Return on equity65%+53.8pp

Debt / equity0.2×-0.1×

Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept auph:TaxesWithheldRelatedToVestingOfPerformanceAwards.

The official record: Aurinia Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's taxes withheld related to vesting of performance awards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aurinia Pharmaceuticals's taxes withheld related to vesting of performance awards?: Aurinia Pharmaceuticals (AUPH) reported taxes withheld related to vesting of performance awards of $943.25K in Q4 2025.
What does taxes withheld related to vesting of performance awards mean?: This represents the cash outflow for tax obligations settled by the company on behalf of employees when performance-based equity awards vest. It highlights the impact of stock-based compensation programs on the company's cash flow and tax liabilities. Investors use this to assess the cash cost of equity-based incentive plans beyond simple dilution.